{"entity":{"id":"nct04550104","kind":"trial","name":"A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT04550104 as recruiting, last updated 2025-12-19. Enrolment is 200 planned participants, an estimate. Interventions: Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390, Ceralasertib, AZD5305, Durvalumab. Primary measures include Dose limiting Toxicities. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04550104","url":"https://clinicaltrials.gov/study/NCT04550104"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04550104","phase":"1","setting":"A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer","sponsor":"University of Leeds","started":"2021-03-17","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04550104/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}